HK Stock Market Move | UNITED LAB (03933) rose more than 4%. New capacity for Gao Lan active pharmaceutical ingredients and Inner Mongolia active pharmaceutical ingredients will be put into operation in October.

UNITED LAB (03933) rose by over 4%, as of press time, it increased by 3.41% to HK$16.96, with a turnover of HK$96.79 million. Furui released a research report stating that UNITED LAB's revenue in the first half of 2025 increased by 5% year-on-year, while net profit increased by 27%. Excluding revenue from business development, it decreased by 50%. Sales of intermediates and APIs dropped by 23% and 27% respectively year-on-year, mainly due to the decline in product prices. UNITED LAB's GLP-1/GIP/GCG triple target receptor agonist UBT251 completed the recruitment of obese patients in April and recruited diabetic patients in May. It has also started recruiting patients for metabolic-related fatty liver disease and chronic kidney disease phase II trials, making progress smoothly. In addition, management indicated that UBT48128, a new class of innovative drug, is scheduled to submit a clinical trial application in the first half of 2026. Management also revealed that the new production capacity for Gao Lan APIs and Inner Mongolia APIs is scheduled to be put into operation in October this year.